Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Correlation with disease burden and early detection of recurrence using a novel nucleosome-based plasma based assay in longitudinally monitored neuroblastoma patients

Thursday, February 29, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The presentation titled 'Correlation with disease burden and early detection of recurrence using a novel nucleosome-based plasma based assay in longitudinally monitored neuroblastoma patients' was delivered at the Precision Medicine Workshop in February 2023. The study highlights the potential of a new assay in predicting cancer recurrence in neuroblastoma patients, showcasing its prognostic value. This research could significantly impact early detection strategies in pediatric oncology.
Price reaction · baseline $20.2 (2024-02-28 close) · hit pre-market · 4 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Novel assay shows promise for early detection of recurrence.
  • Data presented at a reputable workshop indicates potential prognostic value.
  • Focus on neuroblastoma patients highlights a critical area in pediatric oncology.

Full Press Release Details

Presentation title: “Correlation with disease burden and early detection of recurrence using a novel nucleosome-based plasma based assay in longitudinally monitored neuroblastoma patients.”
Presented at Precision Medicine Workshop Feb 2023
Himsworth et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What was the focus of the presentation?

The presentation focused on a novel assay for early detection of neuroblastoma recurrence.

Where was the research presented?

The research was presented at the Precision Medicine Workshop in February 2023.

What is the significance of the nucleosome-based assay?

The assay shows potential prognostic value for monitoring disease burden in neuroblastoma patients.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare neuroblastoma cancer detection nucleosome assay precision medicine
Last updated: Feb 29, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk